Minimal PD-1 expression in mouse and human NK cells under diverse conditions.

PD-1 expression is a hallmark of both early antigen-specific T-cell activation and later chronic stimulation suggesting key roles in both naive T-cell priming and memory T-cell responses. Although important similarities exist between T cells and NK cells, there are critical differences reflecting their biology and functions. The putative role of PD-1 expression in NK cell immunoregulation has been controversial. Our objective was to comprehensively assess PD-1 expression on NK cells using multiple sources and readouts. Primary human tumor samples, ex vivo culturing, mouse tumors and viral models were all assessed using flow cytometry, qRT-PCR and RNA sequencing. We demonstrate that under multiple activating conditions, highly purified human and mouse NK cells consistently lack PD-1 expression despite the marked upregulation of other regulatory markers such as TIGIT. We further show that neither NK cells from T-cell deficient Rag2-/- mice nor from transgenic PD-1 reporter mice express PD-1 using tumor or viral infection models. Asialo-GM1 (ASGM1), a receptor commonly targeted for NK-specific depletion, was also expressed on activated T cells co-expressing PD-1 contributing to in vivo effects previously attributed to NK cells. These data have important implications when attempting to discern NK from T cell effects depending on the models used and whether PD-1 blockade will directly impact NK cell therapies.

[1]  Bin Zhang,et al.  Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. , 2019, The Journal of clinical investigation.

[2]  R. Negrin,et al.  Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. , 2019, JCI insight.

[3]  A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer , 2019, Case Medical Research.

[4]  R. Herbst,et al.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis , 2019, Clinical Cancer Research.

[5]  É. Vivier,et al.  Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.

[6]  K. Qu,et al.  Liver‐Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD‐1‐PD‐L1 Axis , 2019, Immunity.

[7]  Qiao Li,et al.  Abstract A014: Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy , 2019, Clinical Trials of Cancer Immunotherapies.

[8]  N. Tumino,et al.  PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression , 2018, Oncoimmunology.

[9]  M. Caligiuri,et al.  The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. , 2019, Cancer discovery.

[10]  S. Vesely,et al.  Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade , 2018, Nature Medicine.

[11]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[12]  É. Vivier,et al.  Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells , 2018, Nature Immunology.

[13]  Huan Wang,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[14]  S. Endres,et al.  Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies , 2018, Scientific Reports.

[15]  J. Tolar,et al.  Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. , 2018, JCI insight.

[16]  C. Crane,et al.  An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells , 2018, Front. Immunol..

[17]  A. Kamphorst,et al.  CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. , 2018, Annual review of medicine.

[18]  Jeffrey S. Miller,et al.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells , 2018, Cancer Immunology, Immunotherapy.

[19]  J. Modiano,et al.  Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial , 2017, Journal of Immunotherapy for Cancer.

[20]  K. Rezvani,et al.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.

[21]  Y. Cheng,et al.  Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers , 2017, Oncogene.

[22]  Z. Tian,et al.  NK Cell Exhaustion , 2017, Front. Immunol..

[23]  Jeffrey S. Miller,et al.  Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. , 2017, Seminars in immunology.

[24]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[25]  Alexander A. Tong,et al.  Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma , 2017, Oncoimmunology.

[26]  J. Modiano,et al.  Canine cancer immunotherapy studies: linking mouse and human , 2016, Journal of Immunotherapy for Cancer.

[27]  Xi Chen,et al.  Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway , 2016, Nature.

[28]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[29]  D. Olive,et al.  PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma , 2016, Oncotarget.

[30]  S. Sen,et al.  Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression , 2016, Genes and Immunity.

[31]  L. Lanier,et al.  Natural killer cell memory in infection, inflammation and cancer , 2016, Nature Reviews Immunology.

[32]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[33]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[34]  Cathrine A. Miner,et al.  Acquisition of Activation Receptor Ligand by Trogocytosis Renders NK Cells Hyporesponsive , 2015, The Journal of Immunology.

[35]  I. Osman,et al.  Reversal of natural killer cell exhaustion by TIM-3 blockade , 2014, Oncoimmunology.

[36]  Jeffrey S. Miller,et al.  Clinical utility of natural killer cells in cancer therapy and transplantation. , 2014, Seminars in immunology.

[37]  V. Kuchroo,et al.  Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade , 2014, Cancer Immunology Research.

[38]  Jeffrey S. Miller,et al.  NK cells in therapy of cancer. , 2014, Critical reviews in oncogenesis.

[39]  E. Plimack,et al.  PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection , 2013, Cancer Immunology Research.

[40]  Y. Kerdiles,et al.  T cell regulation of natural killer cells , 2013, The Journal of experimental medicine.

[41]  Rosanna La Rocca,et al.  Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.

[42]  L. Xerri,et al.  PD-1 is a novel regulator of human B-cell activation. , 2013, International Immunology.

[43]  F. Locatelli,et al.  Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells , 2013, Front. Immun..

[44]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[45]  Y. Kerdiles,et al.  The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells. , 2011, International immunology.

[46]  E John Wherry,et al.  T cell exhaustion , 2011 .

[47]  H. Karasuyama,et al.  NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo , 2011, The Journal of Immunology.

[48]  Dean Anthony Lee,et al.  Expansion, purification, and functional assessment of human peripheral blood NK cells. , 2011, Journal of visualized experiments : JoVE.

[49]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[50]  D. Campana,et al.  Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors , 2010, Clinical Cancer Research.

[51]  F. Locatelli,et al.  Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. , 2009, Clinical immunology.

[52]  Yuan Zhang,et al.  Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells , 2009, Cancer Immunology, Immunotherapy.

[53]  Soo‐Woong Lee,et al.  Interferon-sensitive response element (ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1 (PD-1) in macrophages. , 2008, Biochimica et biophysica acta.

[54]  R. Peebles,et al.  Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection. , 2008, Viral immunology.

[55]  P. Moreau,et al.  Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.

[56]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[57]  T. Whiteside,et al.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use , 1994, Cancer Immunology, Immunotherapy.

[58]  E. Bloemena,et al.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment , 1994, Cancer Immunology, Immunotherapy.

[59]  M. Altfeld,et al.  Standardization of cytokine flow cytometry assays , 2005, BMC Immunology.

[60]  L. Lanier,et al.  Virus-driven evolution of natural killer cell receptors. , 2002, Microbes and infection.

[61]  L. Lanier,et al.  Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors , 2002, Science.

[62]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[63]  R. Vance,et al.  Regulation of the natural killer cell receptor repertoire. , 2001, Annual review of immunology.

[64]  J. Whitton,et al.  NK Markers Are Expressed on a High Percentage of Virus-Specific CD8+ and CD4+ T Cells1 , 2000, The Journal of Immunology.

[65]  C. Feighery,et al.  Collagenase and Dispase enzymes disrupt lymphocyte surface molecules. , 1996, Journal of immunological methods.

[66]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[67]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[68]  J. Gong,et al.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.

[69]  R. Herberman,et al.  Generation and characterization of purified adherent lymphokine-activated killer cells in mice. , 1989, Journal of immunology.

[70]  M. Bennett,et al.  Mechanism of anti-asialo GM1 prevention of graft-vs-host disease: identification of allo-antigen activated T cells. , 1988, The Journal of investigative dermatology.

[71]  A. Santoni,et al.  Reactivity of Anti‐Asialo GM1 Serum With Tumoricidal and Non‐Tumoricidal Mouse Macrophages , 1985, Journal of leukocyte biology.